Haplotypic arrangement in CYP3A locus is associated with side effects of proliferative signal inhibitors in renal transplant recipients

Transplantation

Volumn 91, Issue 1, 2011, Pages

  Bandur, Stepan ^a   Petrasek, Jan ^a   Hribova, Petra ^a   Novotna, Eva ^a   Brabcova, Irena ^a   Viklicky, Ondrej ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYTOCHROME P450 3A; EVEROLIMUS; RAPAMYCIN;

ALLELE; CHOLESTEROL BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG SUBSTITUTION; GENE LOCUS; GENETIC VARIABILITY; GRAFT RECIPIENT; HAPLOTYPE; HETEROZYGOTE; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SIDE EFFECT;

CASE-CONTROL STUDIES; CELL PROLIFERATION; CYTOCHROME P-450 CYP3A; HAPLOTYPES; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; P-GLYCOPROTEIN; PROTEINURIA; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SIROLIMUS; TREATMENT OUTCOME;

EID: 78751666354     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fa94a0     Document Type: Letter

References (9)

1. Webster ACLV, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234.
2. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008;7:1384.
3. Aggarwal DFM, Soliman GA. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. Metabolism 2006;55:794.
4. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383.
5. *1B promoter variant. Environ Mol Mutagen 2003;42:299.
6. Mourad MMG, Wallemacq P, Garrigue V, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005;80:977.
7. Anglicheau DLCD, Lechaton S, Laurent-Puig P, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005;5:595.
8. Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): An integrated software package for population genetics data analysis. Evol Bioinform Online 2005;1:47.
9. Schena FP, Pascoe MD, Alberu J, et al.; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233.